DowJones News
15 Sep, 2021 02:59

DJ BSE: Glenmark Pharmaceuticals Ltd. - Announcement Under Regulation 30 (LODR)-Press Release / Media Release

 The following is a press release from The Stock Exchange, Mumbai: 
 Glenmark concludes post marketing surveillance (PMS) study on Favipiravir (FabiFlu®) in 1000+ COVID-19 patients, findings reinforce the drug's safety and efficacy in real world settings 
 
https://www.bseindia.com/xml-data/corpfiling/AttachLive/d1be0c0b-3dae-40d0-b572-991b9c238ab0.pdf 
 This content was automatically published based on data and/or text from the original source. For feedback, write to singaporeeditors@dowjones.com. 
 

(END) Dow Jones Newswires

September 14, 2021 22:59 ET (02:59 GMT)


News Source: © 2021 Web Financial Group (UK) Limited. All rights reserved and terms of use apply.

Important Legal Notice about News Sources: Pilling and Co Stockbrokers Ltd. is not responsible for the content or accuracy of third party news and we may not share the views of the author or publisher. We provide third party news for your convenience and information only and make no representation or endorsement whatsoever and hereby exclude all liability for any loss or damage that may be incurred by you as a result of your access or use. Please note that third party content may be subject to terms and conditions imposed by the third party owner of that content.

 

Important Legal Notice about News Sources

Pilling and Co Stockbrokers Ltd. is not responsible for the content or accuracy of third party news articles and we may not share the views of the author or publisher.

We provide third party news for your convenience and information only and make no representation or endorsement whatsoever and hereby exclude all liability for any loss or damage that may be incurred by you as a result of your access or use. Please note that third party content may be subject to terms and conditions imposed by the third party owner of that content.